SANTA CLARA, Calif., Oct. 21 /PRNewswire-FirstCall/ -- XenoPort, Inc. announced today that it will release its third quarter financial results on November 2, 2005, at 4:30 p.m. Eastern Time. The Company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
To access the conference call via the Internet, go to www.XenoPort.com. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 1544432.
The replay of the conference call may be accessed via the Internet, at www.XenoPort.com, or via phone at 1-800-642-1687 for domestic callers, or 706-645-9291 for international callers. The reference number to enter the replay of the call is 1544432.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort’s most advanced product candidate, XP13512, has successfully completed a Phase 2b clinical trial for the treatment of restless legs syndrome and a Phase 2a clinical trial for the management of post-herpetic neuralgia. XenoPort has also completed an initial Phase 1 clinical trial of XP19986, a Transported Prodrug of R-baclofen. This trial demonstrated that XP19986 was suitable for twice-a-day dosing and was well tolerated with few adverse events at the doses tested.
To learn more about XenoPort, please visit the web site at www.XenoPort.com.
NOTE: XenoPort is a registered U.S. trademark
XenoPort, Inc.
CONTACT: Jackie Cossmon of XenoPort, Inc., +1-408-616-7295, orir@XenoPort.com
Web site: http://www.xenoport.com/
